BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas — United States, 2009–2014
MarketScan CCAE Sample Characteristics
Annual BRCA Testing Rates from 2009 to 2014
BRCA Testing Rates by Age Group
BRCA Testing Rates by Region
Receipt of Preventive Interventions and Genetic Counseling Among Women Who Received BRCA Testing
- Moyer VA; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:271–81. PubMed
- Howlader N, Noone AM, Krapcho M, et al., eds. SEER cancer statistics review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015. http://seer.cancer.gov/csr/1975_2012
- National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology. Genetic/Familial high risk assessment: breast and ovarian. Version 2.2017. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2017.
- Kim G, Ison G, McKee AE, et al. FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 2015;21:4257–61. CrossRef PubMed
- Fayanju OM, Hwang ES. Contralateral prophylactic mastectomy: aligning patient preferences and provider Recommendations. JAMA Surg 2017;152:282–3. CrossRef PubMed
- US Food and Drug Administration. Niraparib (Zejula). Washington, DC: US Food and Drug Administration; 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm
- US Food and Drug Administration. FDA grants accelerated approval to new treatment for advanced ovarian cancer. Washington, DC: US Food and Drug Administration; 2017. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm533873.htm
- Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;NEJMoa1706450. CrossRef PubMed
- US Department of Health and Human Services. Healthy people 2020. Topics and objectives: genomics. Washington, DC: US Department of Health and Human Services; 2011. Available at https://www.healthypeople.gov/2020/topics-objectives/topic/genomics
- US Department of Labor. FAQs about Affordable Care Act Implementation (part XII). Washington, DC: US Department of Labor; 2013. https://www.dol.gov/sites/default/files/ebsa/about-ebsa/our-activities/resource-center/faqs/aca-part-xii.pdf
- Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL; Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 2015;17:70–87. CrossRef PubMed
- National Society of Genetic Counselors. Professional status survey: executive summary. Chicago, IL: National Society of Genetic Counselors; 2016. http://www.nsgc.org/p/cm/ld/fid=68
- Kinney AY, Steffen LE, Brumbach BH, et al. Randomized noninferiority trial of telephone delivery of BRCA1/2 genetic counseling compared with in-person counseling: 1-year follow-up. J Clin Oncol 2016;34:2914–24. CrossRef PubMed
- Senier L, Kearney M, Orne J. Using public-private partnerships to mitigate disparities in access to genetic services: lessons from Wisconsin. Adv Med Sociol 2015;16:269–305. CrossRefPubMed
- Hilgart JS, Hayward JA, Coles B, Iredale R. Telegenetics: a systematic review of telemedicine in genetics services. Genet Med 2012;14:765–76. CrossRef
- McDonald E, Lamb A, Grillo B, Lucas L, Miesfeldt S. Acceptability of telemedicine and other cancer genetic counseling models of service delivery in geographically remote settings. J Genet Couns 2014;23:221–8. CrossRef PubMed
- Venne V, Meyer LJ. Genetics and the veterans health administration. Genet Med 2014;16:573–5. CrossRef PubMed
- Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE. Physicians’ experiences with BRCA1/2 testing in community settings. J Clin Oncol 2008;26:5789–96. CrossRef PubMed
- Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011;61:327–59. PubMed
- HIPAASpace [Internet]. S3818: HCPCS 2017 code. HIPAASpace; 2017. https://www.hipaaspace.com/Medical_Billing/Coding/Healthcare.Common.Procedure.Coding.System/S3818.
- Lynch J, Berse B. Methods to identify BRCA testing in claims data. Am J Obstet Gynecol 2016;215:133–4. CrossRef PubMed
- Roberts MC, Dusetzina SB. The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. J Community Genet 2017;8:141–6. CrossRef PubMed
- Desai S, Jena AB. Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie’s New York Times editorial. BMJ 2016;355:i6357.
- Myers MF, Chang MH, Jorgensen C, et al. Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices. Genet Med 2006;8:361–70. CrossRef PubMed
- Cragun D, Weidner A, Lewis C, et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer 2017;123:2497–505. CrossRef PubMed
- Cragun D, Bonner D, Kim J, et al. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. Breast Cancer Res Treat 2015;151:169–76. CrossRef PubMed
- Truven Health Analytics. Truven Health MarketScan research databases, commercial claims and encounters Medicare supplemental, data year 2009–2014. Ann Arbor, MI: Truven Health Analytics. http://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases
- US Census Bureau. Geographic terms and concepts—census divisions and census regions. Washington, DC: US Census Bureau; 2010. https://www.census.gov/geo/reference/gtc/gtc_census_divreg.html.
- Freeman JL, Klabunde CN, Schussler N, Warren JL, Virnig BA, Cooper GS. Measuring breast, colorectal, and prostate cancer screening with Medicare claims data. Med Care 2002;40(Suppl):IV-36–IV-42. CrossRef PubMed
- Agency for Healthcare Research and Quality. 2014 National Healthcare Quality and Disparities Report chartbook on rural health care. Pub. No. 15–0007–9-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2015. https://www.ahrq.gov/research/findings/nhqrdr/2014chartbooks/ruralhealth/index.html
- Leonhard JR, Munson PJ, Flanagan JD, et al. Analysis of reimbursement of genetic counseling services at a single institution in a state requiring licensure. J Genet Couns 2017;26:852–8. CrossRef PubMed
- Gustafson SL, Pfeiffer G, Eng C. A large health system’s approach to utilization of the genetic counselor CPT 96040 code. Genet Med 2011;13:1011–4. CrossRef PubMed
- Chen Z, Kolor K, Grosse SD, et al. Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med 2017. In press.
- Heart T, Kalderon E. Older adults: are they ready to adopt health-related ICT? Int J Med Inform 2013;82:e209–31. CrossRef PubMed
- Guo F, Hirth JM, Lin YL, et al. Use of BRCA mutation test in the U.S., 2004–2014. Am J Prev Med 2017;52:702–9. CrossRef PubMed
- Evans DG. Re: Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie’s New York Times editorial. Questionable Questions, Questionable answers. BMJ 2016;355:i6357.
- Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force recommendation. Evidence synthesis no. 101. Pub. No. 12–05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013. https://www.uspreventiveservicestaskforce.org/Page/Document/evidence-summary17/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing
- CDC. Cancer and family history: using genomics for prevention. Atlanta, GA: US Department of Health and Human Services, CDC; 2016 https://www.cdc.gov/cdcgrandrounds/pdf/archives/2016/phgr_april_final.pdf
- Carman KG, Eibner C, Paddock SM. Trends in health insurance enrollment, 2013–15. Health Aff (Millwood) 2015;34:1044–8. CrossRef PubMed
- Aizcorbe A, Liebman E, Pack S, Cutler DM, Chernew ME, Rosen AB. Measuring health care costs of individuals with employer-sponsored health insurance in the U.S.: A comparison of survey and claims data. Stat J IAOS 2012;28:43–51. PubMed
- Wright JD, Chen L, Tergas AI, et al. Underuse of BRCA testing in patients with breast and ovarian cancer. Am J Obstet Gynecol 2016;214:761–3. CrossRef PubMed
- Qin X, Tangka FK, Guy GP Jr, Howard DH. Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. Cancer Causes Control 2017;28:41–8. CrossRef PubMed
- Trivers KF, Rodriguez JL, Cox SL, Crane BE, Duquette D. The activities and impact of state programs to address hereditary breast and ovarian cancer, 2011–2014. Healthcare (Basel) 2015;3:948–63. CrossRef PubMed